Verastem (VSTM) Earns Daily News Impact Rating of 0.31

Press coverage about Verastem (NASDAQ:VSTM) has been trending positive this week, Alpha One Sentiment Analysis reports. The research group, a unit of Accern, identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Verastem earned a daily sentiment score of 0.31 on Alpha One’s scale. Alpha One also gave press coverage about the biopharmaceutical company an impact score of 50 out of 100, indicating that recent news coverage is somewhat likely to have an impact on the stock’s share price in the near future.

Here are some of the news stories that may have effected Alpha One Sentiment Analysis’s rankings:

A number of equities analysts have commented on the stock. Oppenheimer Holdings Inc. assumed coverage on shares of Verastem in a report on Thursday, April 13th. They issued an “outperform” rating and a $6.00 price objective on the stock. Cantor Fitzgerald reiterated a “hold” rating and issued a $2.00 price objective on shares of Verastem in a report on Thursday, May 11th. Cann reiterated an “outperform” rating and issued a $6.00 price objective on shares of Verastem in a report on Wednesday, April 12th. HC Wainwright boosted their price objective on shares of Verastem from $5.00 to $6.50 and gave the stock a “buy” rating in a report on Friday, March 24th. Finally, Zacks Investment Research lowered shares of Verastem from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Verastem presently has a consensus rating of “Buy” and an average price target of $3.64.

Shares of Verastem (VSTM) traded down 2.74% during midday trading on Monday, hitting $2.13. 120,964 shares of the stock were exchanged. The firm’s market cap is $78.79 million. Verastem has a 12-month low of $1.05 and a 12-month high of $2.54. The stock’s 50 day moving average is $2.16 and its 200 day moving average is $1.53.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.35) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.35). On average, equities research analysts forecast that Verastem will post ($1.31) earnings per share for the current fiscal year.

In related news, Director Timothy J. Barberich bought 30,000 shares of the business’s stock in a transaction on Monday, May 15th. The stock was bought at an average price of $2.45 per share, for a total transaction of $73,500.00. Following the transaction, the director now directly owns 69,462 shares in the company, valued at $170,181.90. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Mideast Time and is the sole property of of Mideast Time. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.mideasttime.com/verastem-vstm-earns-daily-news-impact-rating-of-0-31/1752653.html.

About Verastem

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:VSTM”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Verastem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.